Pp. Feuillan et al., Boys with precocious puberty due to hypothalamic hamartoma: Reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy, J CLIN END, 85(11), 2000, pp. 4036-4038
Hypothalamic hamartoma is an important cause of precocious puberty in boys.
Although the GnRH analogs are known to be effective therapy, there are few
studies of the recovery of the pituitary-gonadal aids following long-term
treatment. To this end, we studied 11 boys with HH after 8.8 +/- 3.2 yr (ra
nge, 4.0-12.6) of treatment with the GnRH agonist D-Trp(6),Prog(9),NEt-LHRH
. The patients' levels of LH and FSH, testosterone, testis volume, and body
mass index were compared with those of six normal boys in pubertal stage I
V-V. We found that the patients' mean +/- SD peak GnRH-stimulated LH and FS
H had returned to the normal range by 1 yr after stopping therapy. Whereas
testosterone returned to normal levels by 1 yr, the patients' testis volume
remained smaller than normal until 2 yr after therapy. Ultrasonography rev
ealed diffuse, punctate, echogenic foci in the testicular parenchyma of two
patients; these were first observed during GnRH agonist therapy and persis
ted unchanged after discontinuation of treatment. Neither of these two pati
ents reported pain or testicular discomfort, no mass or irregularity was de
tected by manual examination in either patient at any time, and levels of b
eta -hCG and alpha1-fetoprotein were normal. By 4 yr after therapy, all pat
ients had pubertal stage V pubic hair; their body mass index was not differ
ent from that of the normal boys at any time point. The dimensions of the p
atients' hamartomas did not change during or after therapy, and no patient
reported new neurological symptoms or signs suggestive of an enlarging lesi
on at any time during or after discontinuation of treatment. Two families d
id report episodes of emotional lability and truancy as the patients reente
red puberty after discontinuation of treatment.